NULOJIX® (belatacept), a selective T-cell costimulation blocker, is a soluble
fusion protein consisting of the modified extracellular domain of CTLA-4 fused
to a portion (hinge-CH2-CH3 domains) of the Fc domain of a human immunoglobulin
G1 antibody. Belatacept is produced by recombinant DNA technology in a mammalian
cell expression system. Two amino acid substitutions (L104 to E; A29 to Y) were
made in the ligand binding region of CTLA-4. As a result of these modifications,
belatacept binds CD80 and CD86 more avidly than abatacept, the parent CTLA4-Immunoglobulin
(CTLA4-Ig) molecule from which it is derived. The molecular weight of belatacept
is approximately 90 kilodaltons.
NULOJIX is supplied as a sterile, white or off-white lyophilized powder for
intravenous administration. Prior to use, the lyophile is reconstituted with
a suitable fluid to obtain a clear to slightly opalescent, colorless to pale
yellow solution, with a pH in the range of 7.2 to 7.8. Suitable fluids for constitution
of the lyophile include SWFI, 0.9% NS, or D5W [see DOSAGE AND ADMINISTRATION].
Each 250 mg single-use vial of NULOJIX also contains: monobasic sodium phosphate
(34.5 mg), sodium chloride (5.8 mg), and sucrose (500 mg).
What are the possible side effects of belatacept (Nulojix)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with belatacept. Call your doctor right away if you have signs of infection such as:
- fever, night sweats, tired feeling;
- cough, sore throat, swollen glands;
- flu symptoms, weight loss;
- confusion, change in your mental state;
- problems with thinking or memory;
- problems with speech or...
Read All Potential Side Effects and See Pictures of Nulojix »
Last reviewed on RxList: 7/22/2011
This monograph has been modified to include the generic and brand name in many instances.